KENNEWICK, Wash., April 2, 2007 (PRIME NEWSWIRE) -- Advanced Medical Isotopes Corporation (AMIC) (Pink Sheets:ADMD) announced that as part of its 2007 Corporate Growth Strategy, the company intends to apply for listing on the Over-The-Counter Bulletin Board (OTCBB:BB.OB-NEWS) during 2007.
A listing on the OTC:BB should provide the company's shareholders greater liquidity, increased exposure and greater transparency of the company's operations, as well as increased access to capital markets.
CEO William J. Stokes commented, "Moving from the Pink Sheets to the Over-The-Counter Bulletin Board is certainly an arduous undertaking, nevertheless, we anticipate to meet this objective while creating additional value for our stakeholders. With our aggressive corporate growth strategy, it is essential to move the company to a higher listing."
About AMIC
Advanced Medical Isotopes Corporation is engaged in the development of advanced production systems and processes for bringing previously unavailable medical isotopes to the marketplace and advancing systems for local product production. The field of nuclear medicine has routinely utilized radioisotopes in the diagnosis of disease while new processes are being pioneered for the targeted treatment of diseases such as cancer in preference to surgical techniques. Advanced Medical Isotopes Corporation products support the accessibility to these less invasive therapeutic processes by advancing systems for lower cost production and improving supply availability of medical isotopes to hospitals and clinical treatment centers. For more information, please visit www.advancedmedicalisotopes.com
Forward-Looking Statements
Except for historical information contained herein, the matters set forth in this press release, such as statements relating to the company's ability to drive technological developments and the acceptance and timing of product introductions, are forward-looking statements that are subject to risks and uncertainties, including but not limited to, timely development and acceptance of new products, the impact of competitive products and pricing, the timely development and release of products by suppliers, and other risks.